Q1 26 EPS
$1.15
Q1 26 Revenue
$11.16B
BEAT +1.51%
Est. $11.00B
vs S&P Since Q1 26
-14.6%
TRAILING MARKET
ABT -11.9% vs S&P +2.7%
Market Reaction
Did ABT Beat Earnings? Q1 2026 Results
Abbott Laboratories kicked off 2026 with a solid beat on both top and bottom lines, extending its streak of beating consensus EPS estimates to four consecutive quarters. The healthcare giant posted adjusted EPS of $1.15 for Q1 2026, edging past the $… Read more Abbott Laboratories kicked off 2026 with a solid beat on both top and bottom lines, extending its streak of beating consensus EPS estimates to four consecutive quarters. The healthcare giant posted adjusted EPS of $1.15 for Q1 2026, edging past the $1.15 consensus estimate by 0.33%, while revenue climbed 7.8% year over year to $11.16 billion, ahead of the $11.00 billion Wall Street had anticipated. The quarter's defining event was the March completion of Abbott's $21 billion acquisition of Exact Sciences, which immediately added a new Cancer Diagnostics business to its portfolio and contributed $96 million in revenue from partial-quarter Cologuard and Cancerguard sales, a move that investors and analysts have been closely watching for its long-term impact on Abbott's diagnostics franchise. Medical Devices remained the engine of organic momentum, reaching $5.54 billion with continuous glucose monitor sales alone hitting $2.08 billion, as Abbott faces intensifying competition in that space. Looking ahead, the company projects full-year 2026 adjusted EPS of $5.38 to $5.58 and comparable sales growth of 6.5% to 7.5%, even as Exact Sciences integration absorbs roughly $0.20 of dilution.
Key Takeaways
- • Medical Devices led by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management
- • Continuous glucose monitor sales grew 14.2% on a reported basis
- • Established Pharmaceuticals driven by double-digit growth in several Latin America and Asia Pacific emerging markets
- • Core Laboratory Diagnostics growth driven by U.S., Europe, and Latin America
- • Cancer Diagnostics driven by double-digit Cologuard growth and Cancerguard sales
ABT Forward Guidance & Outlook
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%. Full-year 2026 adjusted diluted EPS is projected at $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences. Second-quarter 2026 adjusted diluted EPS is projected at $1.25 to $1.31. Management expects Nutrition volume growth to improve over the course of the year as strategic pricing actions and new product launches take effect. The Exact Sciences acquisition is expected to contribute accelerating growth.
ABT YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
ABT Revenue by Segment
With YoY comparisons, source: SEC Filings
ABT Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our first-quarter results were aligned with our expectations to start the year. The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.”
— Robert B. Ford, Q1 2026 Earnings Press Release
ABT Earnings Trends
ABT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABT EPS Trend
Earnings per share: estimate vs actual
ABT Revenue Trend
Quarterly revenue: estimate vs actual
ABT Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $1.15 | — | $11.16B | +1.51% |
| Q4 25 BEAT FY | $1.49 | $1.50 | +0.67% | $11.46B | -2.94% |
| FY Full Year | $5.17 | $5.15 | -0.42% | $44.33B | -0.78% |
| Q3 25 BEAT | $1.30 | $1.30 | +0.05% | $11.37B | -0.21% |
| Q2 25 BEAT | $1.25 | $1.26 | +0.80% | $11.14B | +1.08% |
| Q1 25 BEAT | $1.07 | $1.09 | +1.75% | $10.36B | -0.57% |